Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00005589 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | PHASE3 | COMPLETED | 460 | — | — | Oct 1, 1999 | Apr 1, 2013 | Sep 17, 2013 | 131 | Australia, Austria +15 |
| Name | Type | Description |
|---|---|---|
| filgrastim | BIOLOGICAL | - |
| rituximab | BIOLOGICAL | - |
| carmustine | DRUG | - |
| cyclophosphamide | DRUG | - |
| cytarabine | DRUG | - |
| etoposide | DRUG | - |
| melphalan | DRUG | - |
| bone marrow ablation with stem cell support | PROCEDURE | - |
| peripheral blood stem cell transplantation | PROCEDURE | - |
DISEASE CHARACTERISTICS: * Relapsed or resistant follicular non-Hodgkin's lymphoma (NHL) * No evidence of transformation to high grade or diffuse large B-cell NHL * CD20 positive with no evidence of transformation * Achievement of complete remission (CR) or very good partial remission (VGPR) fol...